Log In
BCIQ
Print this Print this
 

fitusiran (ALN-AT3)

  Manage Alerts
Collapse Summary General Information
Company Alnylam Pharmaceuticals Inc.
DescriptionRNAi therapeutic targeting anti-thrombin III (AT3; SERPINC1) mRNA
Molecular Target Anti-thrombin III (AT3) (SERPINC1)
Mechanism of ActionGene silencing
Therapeutic ModalityNucleic acid: Linear RNA
Latest Stage of DevelopmentPhase I
Standard IndicationHemophilia
Indication DetailsTreat hemophilia; Treat hemophilia A; Treat hemophilia B
Regulatory Designation U.S. - Orphan Drug (Treat hemophilia B);
U.S. - Orphan Drug (Treat hemophilia A);
EU - Orphan Drug (Treat hemophilia)
PartnerSanofi

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$775.0M

0

$75.0M


 Deals Details
Get a free BioCentury trial today